Sign Out
The following should be noted in the case of blood-formation disorders and/or neurological disorders: Due to the serious nature of the disease and the possible sequelae in the event of an inadequate response or lack of patient compliance with the treatment plan, the success of oral treatment should generally be strictly monitored. It is recommended that seven days after the start of treatment, the symptoms, reticulocyte count, a blood count (including haemoglobin -Hb and haematocrit -Hk levels) are checked, as well as the mean corpuscular volume (MCV).
Then the symptoms, blood count and MCV should be monitored at 4-weekly intervals for the first three months of treatment and if patient compliance is good, again at six-monthly/annual intervals.
If a lack of patient compliance is suspected, more frequent controls may be necessary. Caution is advised in patients with folic acid deficiency. Folate deficiency may blunt therapeutic response. In these patients the use of Cyanocobalamin 1000 µg coated tablets is not indicated.
Patients with rare hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption, rare hereditary fructose intolerance or sucrase-isomaltase deficiency should not take Cyanocobalamin 1000 µg coated tablets.
Effects on ability to drive and use machines: None.
Continue with Google